Loading…
Burning Rock Biotech Limited is projected to decline to $10.87 by 2027, a -11% move from its current price of $12.17. BNR is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $11.50 | $12.17 | $12.88 | +0.01% |
| May 30 | $11.24 | $12.17 | $13.18 | +0.02% |
| May 31 | $11.04 | $12.17 | $13.42 | +0.03% |
| Jun 1 | $10.88 | $12.18 | $13.63 | +0.04% |
| Jun 2 | $10.73 | $12.18 | $13.81 | +0.05% |
| Jun 3 | $10.61 | $12.18 | $13.98 | +0.07% |
| Jun 4 | $10.49 | $12.18 | $14.14 | +0.08% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $10.49 | $12.18 | $14.14 | +0.08% |
| Week 2 | $9.87 | $12.19 | $15.05 | +0.15% |
| Week 3 | $9.42 | $12.20 | $15.80 | +0.23% |
| Week 4 | $9.06 | $12.21 | $16.45 | +0.30% |
| Week 5 | $8.75 | $12.22 | $17.06 | +0.38% |
| Week 6 | $8.48 | $12.23 | $17.62 | +0.46% |
| Week 7 | $8.24 | $12.23 | $18.16 | +0.53% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People’s Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services.
The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types using tissue and liquid biopsy samples. Its key products include OncoScreen Focus, a multi-gene tumor mutation co-detection test kit for NSCLC patients; OncoScreen Plus, a pan-cancer test for tissue samples; OncoCompass Plus, a corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; and ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal and related cancers. It also provides CanCatch, a pre-operative ctDNA detection and post-operative minimal residual disease calling for relapsed patients; OncoMaster, an automatic NGS data analysis and report interpretation machine; as well as Magnis BR-customized version of its key products.
In addition, it engages in the facilitation of laboratory equipment sales and sales of reagent kits.
Burning Rock Biotech Limited was founded in 2014 and is headquartered in Guangzhou, the People’s Republic of China. It has a development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA.
BNR operates in Healthcare with a current price of $12.17 and a market cap of $128.35M, ranking 4066. The year-by-year forecast shows a varied path, starting around $12.17 in 2026 and moving to higher levels by 2030 and beyond, with a max forecast of $83.92 and an overall long-term upside indicated by ROIs reaching 199.8 by 2050.
The 30-day technical picture sits at a neutral stance, while the forecast suggests a gradual, bullsih tilt into the late 2020s and 2030s. The stock’s proximity to its 30-day support and resistance levels hints at potential near-term caution, but the longer horizon shows meaningful upside in several years.
A major floor 56.6% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 84.9% above — a clean break opens room to run.
A major ceiling 237.4% above — clearing it would confirm fresh momentum.
Key BNR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BNR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $14.80 | Sell | $14.33 | Sell |
| MA 10 | $15.98 | Sell | $15.35 | Sell |
| MA 20 | $16.39 | Sell | $16.34 | Sell |
| MA 50 | $17.66 | Sell | $18.21 | Sell |
| MA 100 | $22.80 | Sell | $19.18 | Sell |
| MA 200 | $17.61 | Sell | $17.36 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 26.84 | Buy |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -328.58 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.35 | Sell |
| ROC (12) | -27.39 | Sell |
| Bollinger %B (20,2) | -0.31 | Buy |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.59 | Sell |
| Awesome (5,34) | -2.89 | Sell |
| Ultimate (7,14,28) | 10.82 | Buy |
| Momentum (10) | -4.66 | Sell |
| Aroon Osc (25) | -96.00 | Sell |
| Hull MA (9) | 13.40 | Sell |
| ADX (14) | 19.82 | Neutral |
| ATR (14) | 0.77 | Info |
Near-term sentiment is NEUTRAL. The RSI(14) is 30, with the SMA50 at $17.66 and the SMA200 at $17.61, indicating mixed medium-term momentum.
Key support sits at $12.17 and resistance at $22.50, framing the current trading context. The 30-day range spans from a low of $8.39 to a high of $17.65, illustrating recent volatility within a relatively tight band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $12.17 | $12.17 | $14.33 | 0% | Neutral | |
| $7.83 | $10.87 | $16.35 | -11% | Neutral | |
| $9.99 | $14.74 | $23.56 | +21% | Bullish | |
| $10.13 | $15.72 | $26.35 | +29% | Bullish | |
| $10.48 | $17.05 | $29.73 | +40% | Bullish | |
| $10.10 | $17.16 | $30.96 | +41% | Bullish | |
| $8.34 | $14.78 | $27.47 | +21% | Bullish | |
| $8.00 | $14.77 | $28.21 | +21% | Bullish | |
| $8.92 | $17.12 | $33.52 | +41% | Bullish | |
| $11.40 | $22.74 | $45.55 | +87% | Bullish | |
| $11.27 | $25.06 | $55.11 | +106% | Bullish | |
| $16.42 | $36.49 | $83.92 | +200% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $12.17 | $12.17 | $14.33 | +0.00% |
| June 2026 | $9.86 | $11.82 | $14.69 | -2.87% |
| July 2026 | $10.08 | $12.29 | $15.67 | +3.97% |
| August 2026 | $9.49 | $11.73 | $15.23 | -4.60% |
| September 2026 | $8.49 | $10.61 | $14.00 | -9.54% |
| October 2026 | $8.42 | $10.63 | $14.23 | +0.26% |
| November 2026 | $8.63 | $11.00 | $14.90 | +3.42% |
| December 2026 | $8.14 | $10.46 | $14.33 | -4.88% |
Click any year to see its month-by-month BNR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect BNR to range from $12.17 to $14.33 through 2026. The $12.17 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The BNR price prediction for 2027 points to an average of $10.87 (low $7.83, high $16.35) — a potential decline of -11% on today's $12.17. Price action looks broadly range-bound.
In 2028, BNR is projected to trade between $9.99 and $23.56, averaging $14.74 — a potential gain of +21% from today's $12.17. That is up +36% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Burning Rock Biotech Limited's 2029 outlook centres on $15.72, within a $10.13 to $26.35 range. That is up +7% on the projected 2028 average. That marks a +29% change versus current levels. Momentum favours further upside here.
By 2030, BNR could reach as high as $29.73, with a base case around $17.05 and support toward $10.48 — roughly +40% from $12.17. Buyers look set to stay in control over this stretch.
Expect BNR to range from $10.10 to $30.96 through 2031. The $17.16 average target implies a +41% move from current prices. That is up +1% on the projected 2030 average. Momentum favours further upside here.
The BNR price prediction for 2032 points to an average of $14.78 (low $8.34, high $27.47) — a potential gain of +21% on today's $12.17. Buyers look set to stay in control over this stretch.
In 2033, BNR is projected to trade between $8.00 and $28.21, averaging $14.77 — a potential gain of +21% from today's $12.17. That is 0% versus the projected 2032 average. Momentum favours further upside here.
Burning Rock Biotech Limited's 2034 outlook centres on $17.12, within a $8.92 to $33.52 range. That is up +16% on the projected 2033 average. That marks a +41% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, BNR could reach as high as $45.55, with a base case around $22.74 and support toward $11.40 — roughly +87% from $12.17. Momentum favours further upside here.
Expect BNR to range from $11.27 to $55.11 through 2040. The $25.06 average target implies a +106% move from current prices. That is up +10% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The BNR price prediction for 2050 points to an average of $36.49 (low $16.42, high $83.92) — a potential gain of +200% on today's $12.17. Momentum favours further upside here.
Investing $1,000 in BNR today (≈ 82.169269 BNR) could be worth
$2,998.15
+$1,998.15 (+200%) by 2050 · US Dollar
Based on the average projected BNR price of $36.49 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BNRwould be worth at today's price.
$1,000 invested in BNR on May 27, 2025 (≈ 303.951371 BNR) would be worth
$3,699.09
+$2,699.09 (+269.9%) today · 3.70× · US Dollar
Based on a BNR entry price of $3.29 vs. today's $12.17.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $16.7 | $728.74 | -27.1% |
| 1 month ago | $19.06 | $638.51 | -36.1% |
| 3 months ago | $23.86 | $510.06 | -49.0% |
| 6 months ago | $21.59 | $563.69 | -43.6% |
| 1 year ago | $3.29 | $3,699.09 | +269.9% |
| All time (5.0y) ago | $272 | $44.74 | -95.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BNR forecast.
Our base-case forecast reaches $24.00 around 2040.
Implied market cap at $24.00: $211.53M
The multi-year forecast points to a bullish trajectory over the long run. The 2030 forecast shows an avg of $17.05 with a max of $29.73 and an ROI of 40.1, while 2040 carries an avg of $25.06 with a max of $55.11 and an ROI of 105.9. By 2050, the avg forecast reaches $36.49 with a max of $83.92 and an ROI of 199.8, suggesting substantial upside if the paths materialize.
Earlier years exhibit more modest gains or declines, such as 2027 with an avg of $10.87 and an ROI of -10.7, and 2028 with an avg of $14.74 and an ROI of 21.1. The progression from 2029 onward reflects strengthening averages and higher ROIs, culminating in the late-2030s to 2050 where the model signals significant upside. These are estimates, not guarantees, and reflect forecasted paths subject to market conditions and company performance.
Long-term risk is underscored by notable volatility potential (annualized volatility 100%).
Tap a question to reveal the answer.
Avg $17.05; min $10.48; max $29.73; ROI 40.1.
Forecasts show mixed near-term signals (2026 avg $12.17, ROI 0; 2027 avg $10.87, ROI -10.7) but bullish potential later (2030 avg $17.05, ROI 40.1; 2040 ROI 105.9; 2050 ROI 199.8). These are estimates, not guarantees.
Yes—the 2050 max forecast is $83.92, which exceeds $60, though this is not guaranteed and depends on future conditions.
Current price is $12.17 and market cap is $128.35M.
RSI(14) is 30 with NEUTRAL sentiment. SMA50 is $17.66 and SMA200 is $17.61; support is $12.17 and resistance is $22.50. The 30-day range runs from $8.39 to $17.65.
Burning Rock Biotech Limited Community Discussion
0Share your Burning Rock Biotech Limited price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.